Today | ||||
On The Fly
|
Here's What You Missed in Cannabis This Week »
11:29 02/02/23 02/0211:29 02/02/2311:29
IGC
India Globalization Capital
Tilray
Stem Holdings
InterCure
High Tide
Flora Growth
Greenlane
Ayr Wellness
Aurora Cannabis
CV Sciences
CannTrust
Canopy Growth
Cronos Group
Trees Corporation
Goodness Growth
Green Thumb Industries
Trulieve Cannabis
Zynerba
Atai Life Sciences
Compass Pathways
Relmada Therapeutics
In this week's "Rising… ShowHide Related Items >><<
| |||
Options
|
Unusually active option classes on open February 2nd »
09:40 02/02/23 02/0209:40 02/02/2309:40
AKTS
Akoustis
iShares Gold Trust
Vroom
C3.ai
Tilray
Teck Resources
Health Care Select Sector SPDR
Bitfarms
Cameco
ARK Innovation ETF
Unusual total active… Story temporarily locked. ShowHide Related Items >><<
| |||
Hot Stocks
|
SweetWater Brewing Company adds crisp lager to year-round lineup »
07:16 02/02/23 02/0207:16 02/02/2307:16
TLRY
Tilray
SweetWater Brewing… Story temporarily locked. ShowHide Related Items >><<
|
Yesterday | ||||
Options
|
Largest borrow rate increases among liquid names »
08:45 02/01/23 02/0108:45 02/01/2308:45
XM
Qualtrics
GDS Holdings
Litton Ind
QuantumScape
Carvana
Frontline
MSCI Italy Index
Rumble
Aurora Cannabis
Latest data shows the… Latest data shows the largest indicative borrow rate increases among liquid option names include: Qualtrics International (XM) 6.98% +6.73, GDS Holdings (ADS) (GDS) 3.73% +2.46, Global X Lithium (LIT) 1.73% +0.64, Quantumscape (QS) 19.54% +0.47, Carvana (CVNA) 10.20% +0.46, Frontline (FRO) 3.18% +0.42, SPDR Euro STOXX (FEZ) 1.55% +0.39, iShares Italy (EWI) 8.46% +0.35, Rumble (RUM) 104.32% +0.30, and Aurora Cannabis (ACB) 3.74% +0.25. ShowHide Related Items >><<
| |||
Hot Stocks
|
InterCure terminates acquisition agreement with Cann Pharmaceutical »
08:33 02/01/23 02/0108:33 02/01/2308:33
INCR
InterCure
InterCure announces that,… InterCure announces that, further to the merger agreement with Cann Pharmaceutical dated as of February 13, 2022, pursuant to which and subject to its terms, InterCure was to acquire 100% of the issued and outstanding shares of Better, and further to the Company's press release dated November 23, 2022 regarding the fundamental disagreements between the parties, that the closing conditions contained in the Agreement were not met and the Agreement was terminated. In accordance with the terms of the Agreement, the Agreement terminates automatically if the closing conditions and the merger are not completed by 5:00 pm on 31st of January 2023. Accordingly, and in light of the fact that the closing conditions were not met by such date, the Agreement was automatically terminated. Intercure is owed significant amounts loaned and advanced to Better, and since the Agreement was terminated, it intends to recover said amounts under all legal means available to it. ShowHide Related Items >><<
|
Monday | ||||
Hot Stocks
|
TerrAscend closes on acquisition of Allegany Medical Marijuana Dispensary »
09:59 01/30/23 01/3009:59 01/30/2309:59
TRSSF
TerrAscend
TerrAscend announced the… TerrAscend announced the closing of its previously announced acquisition of Allegany Medical Marijuana Dispensary, a medical dispensary in Cumberland, Maryland. Under the terms of the agreement, TerrAscend has acquired a 100% equity interest in AMMD for total consideration of $10M in cash, in addition to entering into a long-term lease with the option to purchase the real estate. This medical dispensary, located in Northwest Maryland within six miles of both the West Virginia and Pennsylvania borders, generated net revenues in excess of $8M in 2022. In anticipation of adult use later this year, TerrAscend expects to rebrand the 10,000 square foot dispensary as The Apothecarium, the Company's award-winning retail dispensary concept. The dispensary will carry TerrAscend's full selection of high-quality branded products, including Gage, Kind Tree, Valhalla, and Wana edibles, subject to regulatory approval. TerrAscend's retail footprint now includes 32 dispensaries nationwide. ShowHide Related Items >><<
| |||
Downgrade
|
Ayr Wellness downgraded to Speculative Buy from Buy at Canaccord »
07:23 01/30/23 01/3007:23 01/30/2307:23
AYRWF
Ayr Wellness
Canaccord analyst Matt… Canaccord analyst Matt Bottomley downgraded Ayr Wellness to Speculative Buy from Buy with a price target of C$16.50, down from C$21, after the company announced it has terminated its previously disclosed planned acquisition of Gentle Ventures, or "Dispensary 33," an Illinois-based cannabis operator with two retail dispensaries in the Chicago area. Though the firm views the announcement as incrementally positive in the near-term, it has lowered its estimated long-term contribution from state as a result. However, Canaccord noted that its lower recommendation is not a function of the deal headline, but rather increased concerns over the ability for the company to manage its debt load and the fact that its thinks "the prospect for a material valuation re-rating more speculative in nature" with Ayr's share price down more than 60% since November of last year. ShowHide Related Items >><<
|
Friday | ||||
Hot Stocks
|
Charlotte's Web 'encouraged' after FDA statement, agrees on testing's importance »
14:49 01/27/23 01/2714:49 01/27/2314:49
CWBHF
Charlotte's Web
Charlotte's Web… Charlotte's Web issued the following statement regarding the FDA's January 26th press announcement: "Charlotte's Web is encouraged that the Administration has agreed that it is necessary for Congress to act for the regulation of hemp-derived cannabidiol, or 'CBD.' The FDA position has taken four years to come together, while the CBD industry has matured without a clear regulatory pathway for CBD products that are already available for sale in all 50 states and consumed safely by millions of Americans. This includes professional athletes, veterans, and everyday wellness seekers. The company looks forward to continuing its work in Washington DC to forward this process. The company also agrees with the FDA on the importance of testing to ensure the quality and safety of CBD products and has already provided studies to support this position. As the CBD pioneer and market leader, Charlotte's Web has engaged in safety studies and compiled toxicology data including liver safety. These studies have been conducted under an Institutional Review Board and Good Laboratory Practices, following guidelines of the Organization for Economic Co-operation and Development. They have been subjected to an unbiased peer review and published in journals and have been vetted and accepted for indexing in the PubMed central database. These studies support the efforts of a legislative regulatory framework. During this four-year period of regulatory absence, Charlotte's Web has set the standard in responsible self-regulation in product manufacturing, safety, and labeling. In addition to safety and toxicology studies the Company utilizes cGMP-compliant manufacturing facilities, seed-to-shelf testing, and certificate of analysis transparency for all products. Recently, Charlotte's Web became the first and only broad-spectrum CBD hemp extract to be NSF Certified for Sport, the gold standard to ensure safe and consistent products for professional athletes and consumers alike." ShowHide Related Items >><<
| |||
Recommendations
|
Aurora Cannabis price target lowered to C$1.45 from C$1.75 at Stifel »
11:06 01/27/23 01/2711:06 01/27/2311:06
ACB
Aurora Cannabis
Stifel analyst W. Andrew… Stifel analyst W. Andrew Carter lowered the firm's price target on Aurora Cannabis to C$1.45 from C$1.75 and keeps a Hold rating on the shares. ShowHide Related Items >><<
| |||
Hot Stocks
|
Ayr Wellness announces mutual termination of Dispensary 33 acquistion »
08:15 01/27/23 01/2708:15 01/27/2308:15
AYRWF
Ayr Wellness
Ayr Wellness announced… Ayr Wellness announced the termination of the Company's previously announced proposed acquisition of the equity interests of Gentle Ventures, LLC d/b/a Dispensary 33, and certain of its affiliates that collectively own and operate two licensed retail dispensaries in Chicago, Illinois. Following the mutual termination, Ayr will no longer be required to pay the previously announced purchase consideration of $55M upfront, including $12M of cash, $3M of sellers notes and $40M of stock. ShowHide Related Items >><<
|